81.19
+0.92(+1.15%)
Currency In USD
| Previous Close | 80.27 |
| Open | 80.51 |
| Day High | 81.96 |
| Day Low | 80.01 |
| 52-Week High | 81.96 |
| 52-Week Low | 29.17 |
| Volume | 1.35M |
| Average Volume | 2.38M |
| Market Cap | 15.7B |
| PE | -15.64 |
| EPS | -5.19 |
| Moving Average 50 Days | 67.42 |
| Moving Average 200 Days | 46.29 |
| Change | 0.92 |
If you invested $1000 in Revolution Medicines, Inc. (RVMD) since IPO date, it would be worth $2,809.34 as of December 25, 2025 at a share price of $81.19. Whereas If you bought $1000 worth of Revolution Medicines, Inc. (RVMD) shares 3 years ago, it would be worth $3,690.45 as of December 25, 2025 at a share price of $81.19.
For more details, use our stock calculator to calculate how much you would've made investing different amounts on specific dates.
Revolution Medicines Announces First Patient Randomized in the RASolute 304 Clinical Trial of Daraxonrasib in Resectable Pancreatic Ductal Adenocarcinoma Following Adjuvant Chemotherapy
GlobeNewswire Inc.
Dec 18, 2025 1:00 PM GMT
REDWOOD CITY, Calif., Dec. 18, 2025 (GLOBE NEWSWIRE) -- Revolution Medicines, a late-stage clinical oncology company developing targeted therapies for patients with RAS-addicted cancers, today announced the first patient has been randomized in the
Revolution Medicines Reports Third Quarter 2025 Financial Results and Update on Corporate Progress
GlobeNewswire Inc.
Nov 05, 2025 9:02 PM GMT
Company is winding down global enrollment for the RASolute 302 clinical trial studying daraxonrasib in patients with previously treated PDAC and remains on track for data readout in 2026Company has initiated RASolute 304, a Phase 3 clinical trial of
Revolution Medicines to Participate in November 2025 Investor Conferences
GlobeNewswire Inc.
Nov 04, 2025 9:05 PM GMT
REDWOOD CITY, Calif., Nov. 04, 2025 (GLOBE NEWSWIRE) -- Revolution Medicines, Inc. (Nasdaq: RVMD), a late-stage clinical oncology company developing targeted therapies for patients with RAS-addicted cancers, today announced that Mark A. Goldsmith,